Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Pancreatic Neoplasms 23Breast Neoplasms 19Carcinoma, Non-Small-Cell Lung 12Neoplasm Metastasis 11Triple Negative Breast Neoplasms 8Neoplasms 5Small Cell Lung Carcinoma 4Sarcoma 4Ovarian Neoplasms 4Lymphoma, Non-Hodgkin 4Lung Neoplasms 4Hodgkin Disease 4Breast Neoplasms, Male 4Stomach Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Multiple Myeloma 3Urinary Bladder Neoplasms 2Recurrence 2Prostatic Neoplasms 2Melanoma 2Lymphoma 2Head and Neck Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Pancreatic Ductal 2Carcinoma 2Uterine Cervical Neoplasms 1Thrombocytosis 1Stages II-III Breast Cancer 1Spinal Cord Compression 1Rectal Neoplasms 1

Interventions

Pemetrexed 3Carboplatin 3HM781-36B 2Gemcitabine 2pembrolizumab 1osimertinib 1aumolertinib 1aflutinib 1Taxes 1Paclitaxel 1Erlotinib Hydrochloride 1Clinical Trials, Phase I as Topic 1Cisplatin 1Bortezomib 1BID protein, human 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × NSCLC × Albumin-Bound Paclitaxel × Clear all
NCT05493501 2024-05-02

Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

EQRx International, Inc.

Phase 3 Terminated
8 enrolled 7 charts
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡